PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations
- Authors:
- more »
- Publication Date:
- Research Org.:
- Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
- Sponsoring Org.:
- INDUSTRY
- OSTI Identifier:
- 1182329
- Grant/Contract Number:
- AC02-06CH11357
- Resource Type:
- Accepted Manuscript
- Journal Name:
- Proceedings of the National Academy of Sciences of the United States of America
- Additional Journal Information:
- Journal Volume: 112; Journal Issue: 11; Journal ID: ISSN 0027-8424
- Publisher:
- National Academy of Sciences, Washington, DC (United States)
- Country of Publication:
- United States
- Language:
- ENGLISH
- Subject:
- 59 BASIC BIOLOGICAL SCIENCES
Citation Formats
Zou, Helen Y., Li, Qiuhua, Engstrom, Lars D., West, Melissa, Appleman, Vicky, Wong, Katy A., McTigue, Michele, Deng, Ya-Li, Liu, Wei, Brooun, Alexei, Timofeevski, Sergei, McDonnell, Scott R. P., Jiang, Ping, Falk, Matthew D., Lappin, Patrick B., Affolter, Timothy, Nichols, Tim, Hu, Wenyue, Lam, Justine, Johnson, Ted W., Smeal, Tod, Charest, Al, and Fantin, Valeria R. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. United States: N. p., 2015.
Web. doi:10.1073/pnas.1420785112.
Zou, Helen Y., Li, Qiuhua, Engstrom, Lars D., West, Melissa, Appleman, Vicky, Wong, Katy A., McTigue, Michele, Deng, Ya-Li, Liu, Wei, Brooun, Alexei, Timofeevski, Sergei, McDonnell, Scott R. P., Jiang, Ping, Falk, Matthew D., Lappin, Patrick B., Affolter, Timothy, Nichols, Tim, Hu, Wenyue, Lam, Justine, Johnson, Ted W., Smeal, Tod, Charest, Al, & Fantin, Valeria R. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. United States. https://doi.org/10.1073/pnas.1420785112
Zou, Helen Y., Li, Qiuhua, Engstrom, Lars D., West, Melissa, Appleman, Vicky, Wong, Katy A., McTigue, Michele, Deng, Ya-Li, Liu, Wei, Brooun, Alexei, Timofeevski, Sergei, McDonnell, Scott R. P., Jiang, Ping, Falk, Matthew D., Lappin, Patrick B., Affolter, Timothy, Nichols, Tim, Hu, Wenyue, Lam, Justine, Johnson, Ted W., Smeal, Tod, Charest, Al, and Fantin, Valeria R. Mon .
"PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations". United States. https://doi.org/10.1073/pnas.1420785112. https://www.osti.gov/servlets/purl/1182329.
@article{osti_1182329,
title = {PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations},
author = {Zou, Helen Y. and Li, Qiuhua and Engstrom, Lars D. and West, Melissa and Appleman, Vicky and Wong, Katy A. and McTigue, Michele and Deng, Ya-Li and Liu, Wei and Brooun, Alexei and Timofeevski, Sergei and McDonnell, Scott R. P. and Jiang, Ping and Falk, Matthew D. and Lappin, Patrick B. and Affolter, Timothy and Nichols, Tim and Hu, Wenyue and Lam, Justine and Johnson, Ted W. and Smeal, Tod and Charest, Al and Fantin, Valeria R.},
abstractNote = {},
doi = {10.1073/pnas.1420785112},
journal = {Proceedings of the National Academy of Sciences of the United States of America},
number = 11,
volume = 112,
place = {United States},
year = {Mon Mar 02 00:00:00 EST 2015},
month = {Mon Mar 02 00:00:00 EST 2015}
}
Free Publicly Available Full Text
Publisher's Version of Record
Other availability
Cited by: 195 works
Citation information provided by
Web of Science
Web of Science
Save to My Library
You must Sign In or Create an Account in order to save documents to your library.
Works referenced in this record:
The transcriptional landscape and mutational profile of lung adenocarcinoma
journal, September 2012
- Seo, J. -S.; Ju, Y. S.; Lee, W. -C.
- Genome Research, Vol. 22, Issue 11
An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms
journal, April 2007
- Zou, H. Y.; Li, Q.; Lee, J. H.
- Cancer Research, Vol. 67, Issue 9
Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Anaplastic Lymphoma Kinase and c-Ros Oncogene 1
journal, July 2014
- Yamazaki, Shinji; Lam, Justine L.; Zou, Helen Y.
- Journal of Pharmacology and Experimental Therapeutics, Vol. 351, Issue 1
Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma
journal, January 2011
- Gu, Ting-Lei; Deng, Xiaxing; Huang, Feizhou
- PLoS ONE, Vol. 6, Issue 1
The protein tyrosine kinase family of the human genome
journal, November 2000
- Robinson, Dan R.; Wu, Yi-Mi; Lin, Su-Fang
- Oncogene, Vol. 19, Issue 49
Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib
journal, April 2014
- Ou, Sai-Hong Ignatius; Azada, Michele; Hsiang, David J.
- Journal of Thoracic Oncology, Vol. 9, Issue 4
A Cre/LoxP conditional luciferase reporter transgenic mouse for bioluminescence monitoring of tumorigenesis
journal, October 2009
- Woolfenden, Steve; Zhu, Haihao; Charest, Al
- genesis, Vol. 47, Issue 10
Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1
journal, June 2013
- Awad, Mark M.; Katayama, Ryohei; McTigue, Michele
- New England Journal of Medicine, Vol. 368, Issue 25
Potentially actionable kinase fusions in inflammatory myofibroblastic tumors.
journal, May 2013
- Lovly, Christine Marie; Lipson, Doron; Otto, Geoff
- Journal of Clinical Oncology, Vol. 31, Issue 15_suppl
Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
journal, November 2013
- Gainor, Justin F.; Shaw, Alice T.
- Journal of Clinical Oncology, Vol. 31, Issue 31
Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma
journal, January 2003
- Charest, A.; Kheifets, V.; Park, J.
- Proceedings of the National Academy of Sciences, Vol. 100, Issue 3
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins
journal, November 2013
- Davare, M. A.; Saborowski, A.; Eide, C. A.
- Proceedings of the National Academy of Sciences, Vol. 110, Issue 48
Insight into Crizotinib Resistance Mechanisms Caused by Three Mutations in ALK Tyrosine Kinase using Free Energy Calculation Approaches
journal, August 2013
- Sun, Huiyong; Li, Youyong; Li, Dan
- Journal of Chemical Information and Modeling, Vol. 53, Issue 9
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
journal, February 2008
- Engelman, Jeffrey A.; Settleman, Jeffrey
- Current Opinion in Genetics & Development, Vol. 18, Issue 1
Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non-Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion
journal, June 2012
- Rimkunas, V. M.; Crosby, K. E.; Li, D.
- Clinical Cancer Research, Vol. 18, Issue 16
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
journal, November 2001
- Bhattacharjee, A.; Richards, W. G.; Staunton, J.
- Proceedings of the National Academy of Sciences, Vol. 98, Issue 24
Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement.
journal, May 2012
- Shaw, Alice Tsang; Camidge, D. Ross; Engelman, Jeffrey A.
- Journal of Clinical Oncology, Vol. 30, Issue 15_suppl
The landscape of kinase fusions in cancer
journal, September 2014
- Stransky, Nicolas; Cerami, Ethan; Schalm, Stefanie
- Nature Communications, Vol. 5, Issue 1
Kinase fusions are frequent in Spitz tumours and spitzoid melanomas
journal, January 2014
- Wiesner, Thomas; He, Jie; Yelensky, Roman
- Nature Communications, Vol. 5, Issue 1
Diversity of Mechanism-Based Pharmacodynamic Models
journal, May 2003
- Mager, Donald E.; Wyska, Elzbieta; Jusko, William J.
- Drug Metabolism and Disposition, Vol. 31, Issue 5
Frequencies of ALK and ROS in NSCLC FFPE tumor samples utilizing a highly specific immunohistochemistry-based assay and FISH analysis.
journal, May 2010
- Rimkunas, V.; Crosby, K.; Kelly, M.
- Journal of Clinical Oncology, Vol. 28, Issue 15_suppl
Crizotinib in ROS1 -Rearranged Non–Small-Cell Lung Cancer
journal, November 2014
- Shaw, Alice T.; Ou, Sai-Hong I.; Bang, Yung-Jue
- New England Journal of Medicine, Vol. 371, Issue 21
ALK in Lung Cancer: Past, Present, and Future
journal, March 2013
- Shaw, Alice T.; Engelman, Jeffrey A.
- Journal of Clinical Oncology, Vol. 31, Issue 8
Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer
journal, October 2014
- Katayama, Ryohei; Kobayashi, Yuka; Friboulet, Luc
- Clinical Cancer Research, Vol. 21, Issue 1
Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells
journal, June 2013
- Taipale, Mikko; Krykbaeva, Irina; Whitesell, Luke
- Nature Biotechnology, Vol. 31, Issue 7
Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
journal, August 2012
- Heuckmann, Johannes M.; Balke-Want, Hyatt; Malchers, Florian
- Clinical Cancer Research, Vol. 18, Issue 17
ROS1 as a ‘druggable’ receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway
journal, April 2012
- Ou, Sai-Hong Ignatius; Tan, Jackie; Yen, Yun
- Expert Review of Anticancer Therapy, Vol. 12, Issue 4
ROS Fusion Tyrosine Kinase Activates a SH2 Domain–Containing Phosphatase-2/Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Signaling Axis to Form Glioblastoma in Mice
journal, August 2006
- Charest, Al; Wilker, Erik W.; McLaughlin, Margaret E.
- Cancer Research, Vol. 66, Issue 15
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
journal, September 2011
- Cui, J. Jean; Tran-Dubé, Michelle; Shen, Hong
- Journal of Medicinal Chemistry, Vol. 54, Issue 18
Discovery of (10 R )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- 2H -8,4-(metheno)pyrazolo[4,3- h ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
journal, December 2013
- Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon
- Journal of Medicinal Chemistry, Vol. 57, Issue 11
Chromosome 3 Anomalies Investigated by Genome Wide SNP Analysis of Benign, Low Malignant Potential and Low Grade Ovarian Serous Tumours
journal, December 2011
- Birch, Ashley H.; Arcand, Suzanna L.; Oros, Kathleen K.
- PLoS ONE, Vol. 6, Issue 12
Characterization of ROS1 cDNA from a human glioblastoma cell line.
journal, June 1990
- Birchmeier, C.; O'Neill, K.; Riggs, M.
- Proceedings of the National Academy of Sciences, Vol. 87, Issue 12
Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer
journal, February 2015
- Song, A.; Kim, T. M.; Kim, D. -W.
- Clinical Cancer Research, Vol. 21, Issue 10
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
journal, December 2007
- Rikova, Klarisa; Guo, Ailan; Zeng, Qingfu
- Cell, Vol. 131, Issue 6
RET, ROS1 and ALK fusions in lung cancer
journal, February 2012
- Takeuchi, Kengo; Soda, Manabu; Togashi, Yuki
- Nature Medicine, Vol. 18, Issue 3
Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance
journal, September 2014
- Kodama, Tatsushi; Tsukaguchi, Toshiyuki; Yoshida, Miyuki
- Cancer Letters, Vol. 351, Issue 2
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
journal, March 2012
- Bergethon, Kristin; Shaw, Alice T.; Ignatius Ou, Sai-Hong
- Journal of Clinical Oncology, Vol. 30, Issue 8
Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21)
journal, March 2003
- Charest, Alain; Lane, Keara; McMahon, Kevin
- Genes, Chromosomes and Cancer, Vol. 37, Issue 1
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
journal, November 2005
- Bild, Andrea H.; Yao, Guang; Chang, Jeffrey T.
- Nature, Vol. 439, Issue 7074
Diversity of gene expression in adenocarcinoma of the lung
journal, November 2001
- Garber, M. E.; Troyanskaya, O. G.; Schluens, K.
- Proceedings of the National Academy of Sciences, Vol. 98, Issue 24
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
journal, March 2014
- Friboulet, L.; Li, N.; Katayama, R.
- Cancer Discovery, Vol. 4, Issue 6
ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas
journal, January 2013
- Sholl, Lynette M.; Sun, Heather; Butaney, Mohit
- The American Journal of Surgical Pathology, Vol. 37, Issue 9
Abstract 3764: SC-1, a sorafenib derivative, induces apoptosis in epidermal growth factor receptor wild type non-small cell lung cancer through the inhibition of signal transducers and activators of transcription 3
conference, November 2014
- Wang, Cheng-Yi; Chao, Ting-Ting; Shiau, Chung-Wai
- Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL, Experimental and Molecular Therapeutics
Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib
journal, February 2014
- Huang, Qinhua; Johnson, Ted W.; Bailey, Simon
- Journal of Medicinal Chemistry, Vol. 57, Issue 4
Breakpoint Analysis of Transcriptional and Genomic Profiles Uncovers Novel Gene Fusions Spanning Multiple Human Cancer Types
journal, April 2013
- Giacomini, Craig P.; Sun, Steven; Varma, Sushama
- PLoS Genetics, Vol. 9, Issue 4
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
journal, February 2015
- ,
- New England Journal of Medicine, Vol. 372, Issue 7, p. 683-684
The Oncogenic Lung Cancer Fusion Kinase CD74-ROS Activates a Novel Invasiveness Pathway through E-Syt1 Phosphorylation
journal, July 2012
- Jun, Hyun Jung; Johnson, Hannah; Bronson, Roderick T.
- Cancer Research, Vol. 72, Issue 15
Works referencing / citing this record:
Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors
journal, December 2017
- Sgambato, Assunta; Casaluce, Francesca; Maione, Paolo
- Expert Review of Anticancer Therapy, Vol. 18, Issue 1
Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities
journal, March 2016
- Tabbò, Fabrizio; Pizzi, Marco; Kyriakides, Peter W.
- Oncotarget, Vol. 7, Issue 18
The role of HGF/c-MET signaling pathway in lymphoma
journal, December 2016
- Lam, Bao Quoc; Dai, Lu; Qin, Zhiqiang
- Journal of Hematology & Oncology, Vol. 9, Issue 1
Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC
journal, May 2016
- Bansal, Pranshu; Osman, Diaa; Gan, Gregory N.
- Frontiers in Oncology, Vol. 6
Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches
journal, November 2015
- Shea, Meghan; Costa, Daniel B.; Rangachari, Deepa
- Therapeutic Advances in Respiratory Disease, Vol. 10, Issue 2
Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
journal, January 2017
- Collier, T. Lee; Maresca, Kevin P.; Normandin, Marc D.
- Molecular Imaging, Vol. 16
Targeted therapies and immunotherapy in non-small-cell lung cancer
journal, June 2016
- Cortinovis, D.; Abbate, M.; Bidoli, P.
- ecancermedicalscience, Vol. 10
Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners
journal, May 2020
- Reed, Mollie; Rosales, Aimee-Lauren S.; Chioda, Marc D.
- Advances in Therapy
From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer
journal, January 2019
- Pirker, Robert; Filipits, Martin
- ESMO Open, Vol. 4, Issue 5
ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance
journal, January 2016
- Ye, Mingxiang; Zhang, Xinxin; Li, Nan
- Oncotarget, Vol. 7, Issue 11
Pharmacophore-based designing of putative ROS-1 targeting agents for NSCLC
journal, January 2020
- Pathak, Disha; Choudhary, Shalki; Singh, Pankaj Kumar
- Molecular Diversity
Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK
journal, May 2015
- Rothschild, Sacha
- Cancers, Vol. 7, Issue 2
Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non–small cell lung cancer and the clinical responses based on the resistant mechanisms
journal, February 2020
- Yanagitani, Noriko; Uchibori, Ken; Koike, Sumie
- Cancer Science, Vol. 111, Issue 3
Treatment of ALK -rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context
journal, August 2017
- Itchins, M.; Chia, P. L.; Hayes, S. A.
- Asia-Pacific Journal of Clinical Oncology, Vol. 13
TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity
journal, July 2017
- Ogura, Hayato; Nagatake-Kobayashi, Yuka; Adachi, Jun
- Scientific Reports, Vol. 7, Issue 1
Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start
journal, April 2018
- Facchinetti, Francesco; Friboulet, Luc
- Translational Lung Cancer Research, Vol. 7, Issue S2
Anaplastic lymphoma kinase: Role in cancer and therapy perspective
journal, November 2015
- Zhao, Zhihong; Verma, Vivek; Zhang, Mutian
- Cancer Biology & Therapy, Vol. 16, Issue 12
Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR
journal, July 2017
- Narayanan, Dilip; Gani, Osman A. B. S. M.; Gruber, Franz X. E.
- Journal of Cheminformatics, Vol. 9, Issue 1
Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions
journal, September 2018
- Kato, Yuka; Ninomiya, Kiichiro; Ohashi, Kadoaki
- Cancer Science, Vol. 109, Issue 10
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
journal, February 2018
- Sharma, Geeta; Mota, Ines; Mologni, Luca
- Cancers, Vol. 10, Issue 3
Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing
journal, March 2019
- Dong, Jingsi; Li, Bingjie; Lin, Dan
- Frontiers in Pharmacology, Vol. 10
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
journal, August 2019
- Katayama, Ryohei; Gong, Bo; Togashi, Noriko
- Nature Communications, Vol. 10, Issue 1
Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer
journal, June 2019
- Roys, Annie; Chang, Xing; Liu, Yang
- Cancer Chemotherapy and Pharmacology, Vol. 84, Issue 4
Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib
journal, June 2017
- Collier, Thomas Lee; Normandin, Marc D.; Stephenson, Nickeisha A.
- Nature Communications, Vol. 8, Issue 1
Current Landscape of Targeted Therapy in Lung Cancer
journal, September 2017
- Mayekar, Manasi K.; Bivona, Trever G.
- Clinical Pharmacology & Therapeutics, Vol. 102, Issue 5
Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives
journal, July 2017
- Rossi, Giulio; Jocollé, Genny; Conti, Antonia
- Lung Cancer: Targets and Therapy, Vol. Volume 8
Targeting HGF/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphoma
journal, December 2015
- Dai, Lu; Trillo-Tinoco, Jimena; Cao, Yueyu
- Blood, Vol. 126, Issue 26
Can molecular profiling enhance radiotherapy? Impact of personalized targeted gold nanoparticles on radiosensitivity and imaging of adenoid cystic carcinoma
journal, January 2017
- Hazkani, Inbal; Motiei, Menachem; Betzer, Oshra
- Theranostics, Vol. 7, Issue 16
Conformation of the Macrocyclic Drug Lorlatinib in Polar and Nonpolar Environments: A MD Simulation and NMR Study
journal, December 2019
- Peng, Cheng; Atilaw, Yoseph; Wang, Jinan
- ACS Omega, Vol. 4, Issue 26
The role of HGF/c-MET signaling pathway in lymphoma
journal, December 2016
- Lam, Bao Quoc; Dai, Lu; Qin, Zhiqiang
- Journal of Hematology & Oncology, Vol. 9, Issue 1
Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions
journal, September 2018
- Kato, Yuka; Ninomiya, Kiichiro; Ohashi, Kadoaki
- Cancer Science, Vol. 109, Issue 10
Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments
journal, January 2018
- Latif, Muhammad; Ashraf, Zaman; Basit, Sulman
- RSC Advances, Vol. 8, Issue 30
Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance
journal, August 2017
- Schram, Alison M.; Chang, Matthew T.; Jonsson, Philip
- Nature Reviews Clinical Oncology, Vol. 14, Issue 12
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
journal, August 2019
- Katayama, Ryohei; Gong, Bo; Togashi, Noriko
- Nature Communications, Vol. 10, Issue 1